Mineralys Therapeutics, Inc. (MLYS) vs SELLAS Life Sciences Group, Inc. (SLS)

Mineralys Therapeutics, Inc. and SELLAS Life Sciences Group, Inc. are both Biotechnology companies. Mineralys Therapeutics, Inc. and SELLAS Life Sciences Group, Inc. are of similar size ($2.4B and $2.4B). Across the 9 metrics below, SELLAS Life Sciences Group, Inc. leads on 7 and Mineralys Therapeutics, Inc. on 2.

Valuation

Metric MLYS SLS Biotechnology median
P/E n/m n/m 7.88
P/S n/m 209.18 11.47
P/B 3.98 15.96 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales n/m 196.06 10.73
Earnings yield (16.40%) (1.81%) (28.84%)
Free cash flow yield (6.34%) (1.75%) (23.03%)

Profitability

Metric MLYS SLS Biotechnology median
Gross margin — 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (80.88%) (39.63%) (57.72%)
Return on assets (69.67%) (36.54%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric MLYS SLS Biotechnology median
Revenue growth (TTM) — — 5.64%
EPS growth (last fiscal year) 37.43% 50.00% —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric MLYS SLS Biotechnology median
Debt to equity 0.18 0.00 0.00
Current ratio 34.46 18.83 4.73
Net debt to EBITDA 3.85 2.54 0.96

Dividend

Metric MLYS SLS Biotechnology median
Dividend yield — — 2.10%
Payout ratio — 0.00 0.00

Size

Metric MLYS SLS Biotechnology median
Market cap 2.35b 2.37b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack